SOURCE: Noble Financial Capital Markets
STAMFORD, CT--(Marketwire - Sep 11, 2012) - In two weeks, Noble Financial Capital Markets (Noble) will host BIOX, an investor exposition to be held at the University of Connecticut in Stamford, CT on September 24-25, 2012. The format and content of the event has attracted world-renowned opinion leaders from the scientific community, as well as senior executives from 30 life-sciences companies who will participate in panel presentations and investor meetings.
"This is the first time Noble has organized an event that is laser-focused on the science behind the companies at the forefront of medical innovation," said Rahul Jasuja, Noble's Managing Director of Biotechnology Research. "While there may be several investor conferences out there, none have gone as deep as we will go in areas that most agree will represent the future of therapeutic medicine," he said.
The four areas of concentration at the Exposition are targeted oncology, cell therapy & regenerative medicine, immunotherapy, and tissue engineering & biomaterials. In each of the areas, panel members will present and debate recent developments and progress from both a macro and individual company perspective. Opinion Leaders on each of the panels are as follows:
- Targeted Oncology: Dr. Jeffrey Infante, Executive Director of the Drug Development Program at Sarah Cannon Research Institute
- Immunotherapy and Vaccines: Dr. Phil Greenberg, Head of the Program in Immunology at the Fred Hutchinson Cancer Research Center
- Tissue Engineering and Biomaterials: Dr. Charles Vacanti, Harvard Medical School
- Cell Therapy and Regenerative Medicine: Dr. Mark Noble, Director of the University of Rochester Stem Cell & Regenerative Medicine Institute
The panels will allow for the opinion leaders to present an overview of the topic, and then each of the corporate participants to highlight their lead programs. Fifty percent of the time devoted to each panel will be allocated to an open forum for questions from investors and among panelists. One-hour organized breakouts will follow panel presentations. An evening networking session will allow for the extension of the business day in a more casual atmosphere. The second day will be devoted to private investor meetings with executives.
In addition to the panels and meetings, the Chairman of Noble's Scientific Advisory Board, Jules Müsing, will be a featured speaker at the event. As the former head of Global Drug Licensing at Johnson & Johnson, Mr. Müsing will enlighten investors and executives as to what it takes for small biotech's to gain the attention of large pharmaceutical companies, and how licensing executives can convince their R&D departments and executive committees to make substantial investments in these companies.
Investor participation is by invitation only.
Conference website: http://www.nobleresearch.com/BioExposition.htm